Pfizer & Wyeth: Is Mega Merger A Strategic Move Or Desperate Play?
This article was originally published in The Pink Sheet Daily
Executive Summary
Combination of Pfizer and Wyeth would create a drug powerhouse with combined sales of over $70 billion, strengthen Pfizer’s position in biotech and vaccines and create billions in cost savings opportunities.
You may also be interested in...
A Goliath Grows: Pfizer Buys Wyeth For $68 Billion
Merger propels Pfizer ahead in biotechnology and paves the way for the drug giant to navigate the loss of Lipitor in 2011.
A Goliath Grows: Pfizer Buys Wyeth For $68 Billion
Merger propels Pfizer ahead in biotechnology and paves the way for the drug giant to navigate the loss of Lipitor in 2011.
Wyeth Calls Off Plan To Acquire Crucell
Question remains whether Pfizer or another pharma will make play for Dutch vaccine-focused firm.